Taken together, these rescue experiments demonstrate that fedratinib suppresses ESCC progression through the JAK2/STAT3 pathway by downregulating vimentin, cyclin D1, and survivin, leading to concurrent inhibition of proliferation and migration, along with induction of apoptosis. Here, STAT3 is linked to esophageal squamous cell carcinoma.